Methods
We conducted a literature search to identify randomized controlled trials that compared the effects of supplemental i.v. crystalloids with a conservative fluid regimen for the prevention of PONV in adult and adolescent surgical patients of at least 16 yr of age. Paediatric patients were not included as water contributes to a higher percentage of body weight in children, fluid imbalance causes more morbidity and mortality in this surgical population, and accurate reporting of nausea is generally more difficult in younger patients. Without any language restrictions, a search in July 2011 was performed in PubMed, EMBASE, Web of Science, and the Cochrane Library using the following terms: intravenous infusion; IV; fluid; fluid therapy; fluid therapies; hydration; crystalloid; preoperative; pre-operative; perioperative; perioperative; intraoperative; intra-operative; postoperative; post-operative; postanesthe*; postanaesthe*; post-anesthe*; post-anaesthe*; anesthesia; anaesthesia; surgery; surgical; surgical procedures, operative; PONV; nausea; vomit*; emesis; and retch*. Reference lists of identified studies were hand-searched until no further new trials were identified. The last electronic search was performed in July 2011 and a weekly e-mail notification was activated for potentially relevant new trials.
Two authors (A.M., M.O.-S.) independently reviewed all full reports and abstracts that could potentially meet the inclusion criteria. Dichotomous data on the incidence of postoperative nausea (PON), postoperative vomiting (POV), or both (PONV) from arrival in the PACU up to 72 h after surgery; need for rescue antiemetic medication; and the presence of sideeffects were extracted from all trials by two authors (A.M., M.O.-S.) and analysed separately. If data were not clearly stated in the text or in a table, the information was extracted from graphs, if possible. Any discrepancies in the data or disagreements were settled by a third person (C.C.A.).
PON was defined as an unpleasant sensation associated with the urge to vomit. POV was defined as an attempted expulsion of gastric contents (vomiting or retching). PONV was defined as any nausea, vomiting, or both. Antiemetic rescue treatment was defined as any additional intervention provided for the treatment of established PON, POV, or PONV. Side-effects included any kind of associated adverse outcome that was described.
Incidences were evaluated for three time periods: early, late, and overall. The early period was defined as the highest incidence of nausea (PON) or vomiting (POV) within 6 h after surgery. When event rates were reported for several early intervals, we chose the earliest interval (e.g. 0-2 h instead of 0-6 h) in order to increase the chance of detecting a potential difference in the early vs late time intervals, unless an outlier was suspected. The late period was defined as the time interval nearest to 24 h reporting PON or POV. The overall period was defined as the longest postoperative period starting after completion of surgery and ending with the time reported nearest to 24 h.
Meta-analyses were conducted with Review Manager 5.1 (Cochrane Collaboration, Oxford, UK). Relative risks (RRs) with associated 95% confidence intervals (CIs) of 
Continued
Supplemental i.v. crystalloids for PONV prophylaxis supplemental crystalloid compared with conventional fluid therapy were calculated using a random-effects model. An RR ,1 indicates a potentially beneficial effect, while an RR .1 indicates a potentially adverse effect for the administration of supplemental i.v. crystalloids. P,0.05 was considered statistically significant.
Results
The search identified 33 potentially relevant studies, of which 15 studies met the eligibility criteria for inclusion ( Fig. 1) . Eighteen of the 33 potentially relevant trials were excluded for various reasons: the trial did not report the incidence of PONV, 8 -16 studied a paediatric surgical population, 17 18 compared crystalloids with colloids 19 -21 or examined supplemental colloids, 22 was not a randomized controlled trial, 23 24 or compared crystalloids administered before operation against intraoperatively. 25 Of a total of 1570 patients, 787 patients received supplemental crystalloids and 783 received a conservative fluid regimen (Table 1) 
Postoperative nausea
In only one of the 10 studies did supplemental crystalloids show a significant reduction in early PON, but by grouping and weighing the effects of the individual studies, the cumulative effect of supplemental crystalloids on early PON shows a significant reduction (RR 0.73, 95% CI 0.59 -0.89; P¼0.003) ( 
Adverse side-effects
No studies reported adverse events associated with supplemental fluid administration, such as pulmonary oedema or wound dehiscence, when comparing a liberal i.v. crystalloid regimen with a restricted fluid regimen. However, one study did report that 15% of patients in the i.v. crystalloid group complained of pain along the infusion arm. 37 
Discussion
This systematic review of the efficacy of supplemental i.v. crystalloids for the prevention of PONV suggests that i.v.
crystalloids reduce the incidence of several but not all PONV outcomes. Specifically, i.v. crystalloids significantly reduced early, late, and overall PON, overall POV, and late and overall PONV. The effect of i.v. crystalloids was not statistically significant for early and late POV and early PONV. Supplemental i.v. crystalloids reduced overall PONV and the need for rescue treatment as effectively as many prophylactic antiemetic drugs. 38 39 The mechanism by which i.v. hydration reduces PONV is unclear, although several hypotheses have been proposed. It has previously been believed that surgical patients become hypovolaemic after overnight fasting, and this was Supplemental i.v. crystalloids for PONV prophylaxis thought to lead to organ hypoperfusion, specifically cerebral and intestinal hypoperfusion, which would trigger PONV. I.V. crystalloids were assumed to prevent PONV by maintaining blood volume, mean arterial pressure, and hence organ perfusion. However, a study using the indocyanine green dilution method established that ASA I-III patients undergoing hysterectomy under general anaesthesia remain normovolaemic even after 10 h of fasting. 40 Irrespective of fluid balance, overnight fasting is not typically associated with nausea or vomiting in otherwise healthy individuals. We believe that the effect of supplemental crystalloids on PONV may be mediated by antidiuretic hormone (arginine vasopressin, AVP). Although there is no preoperative hypovolaemia, anaesthetics can induce a relative hypovolaemia through vasodilation with reduced venous return and preload. 41 This leads to reduced central venous pressure with reduced negative feedback of the right atrial stretch receptors, leading to increased AVP release from the posterior pituitary. AVP is strongly associated with nausea and vomiting. A previous study reported that plasma AVP levels are increased right at the onset of surgery and are significantly higher in patients who experience PONV than in those who do not. 42 Other models of nausea and vomiting corroborate these observations. For example, plasma AVP concentrations have been shown to rapidly increase in people who experienced nausea, emesis, or both in response to circular vection, 43 44 apomorphine, 45 and cisplatin. 46 47 AVP was found to be released concurrently with gastric dysrhythmias and reports of nausea in study participants who experienced motion sickness, while no AVP release or slow wave gastric rhythm disruption occurred in participants who did not. 43 Dogs and humans react to i.v. AVP infusions with nausea, retching, and vomiting. 48 Exogenous AVP infusion caused both motion sickness-susceptible and -resistant participants to experience nausea. 43 Vasopressin V 1 receptor antagonists have been shown to prevent the induction of motion sickness in animal models. 49 50 Given that opioid administration is a strong predictor of PONV, 51 it is also interesting to note that morphine administration has been shown to raise plasma AVP levels in ferrets 52 and humans. 53 It is interesting that i.v. hydration seems to have a greater effect on late than on early PONV, considering that crystalloid infusions are redistributed in the body within 90 min. 54 One possible explanation is that rehydration induces longlasting effects by replacing extracellular fluid and/or by dampening the secretion of emetic stress response hormones, whose plasma levels take time to diminish once elevated. 42 This may be of clinical interest because some antiemetics are short-acting and are therefore most effective in the early postoperative period. 55 
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Other outcomes
Although not systematically reported in this review, supplemental crystalloids were also noted to reduce the prevalence of other minor morbidities such as postoperative thirst, 4 27 35 37 dizziness, 4 35-37 drowsiness, 4 37 and headache. 4 Pain scores and analgesic requirements were also significantly reduced by supplemental fluid administration in one study. 6 In the setting of elective minor or moderate surgery, supplemental i.v. crystalloids had virtually no side-effects with the exception of pain reported in the infusion arm in one trial. 37 However, for larger procedures such as major intraabdominal operations, where fluid accumulation is more likely, there is some evidence that supplemental fluids interfere with wound healing and recovery. 9 57 58 A limitation of our study is that nearly half of the studies included had sample sizes of ,50 patients per treatment group, and, given a realistic RR reduction of about 30% (e.g. from 40% to 28%), a 50-patient sample size has only 20% power to detect such a difference at a two-sided P-value of 0.05. 38 59 This may explain, in part, why not all PONV outcomes reached statistical significance, even when the effect size was in the expected range. A further limitation is that the trials included in our meta-analysis studied a wide range of supplemental fluid volumes, from 2 to 30 ml kg
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, and also fluids given during both the preoperative and the intraoperative periods. While this review was not designed to evaluate the relative efficacy of different supplemental fluid volumes or timing, our results may suggest that providing supplemental fluids improved PONV outcomes compared with a restricted fluid regimen, regardless of the definition of 'supplemental' and 'restricted' regimens (Fig. 2) . This is further supported by the fact that the tests for heterogeneity were not statistically significant in the majority of cases, that is, irrespective of the specific amounts and Supplemental i.v. crystalloids for PONV prophylaxis timing used in the individual studies. However, the findings of some previous meta-analyses of relatively small studies have been refuted by subsequent large, well-designed trials. 60 61 Therefore, despite these promising results, a well-powered study will be required to definitively determine whether supplemental i.v. crystalloids reduce a range of PONV outcomes. Several trials showed a possible or high risk of bias on one or more components of methodological quality (Fig. 3) . We used the Cochrane risk of bias scale to assess study quality. 62 Inclusion of studies of poor methodological quality may over-or under-estimate the overall effect. 63 However, it may be a problem to exclude a trial entirely based on a quality threshold, especially if the study is adequately randomized and blinded, and the use of quality assessment in reviews is not universally recommended. 64 Sensitivity analysis would clarify whether inclusion of lower quality studies biased our results. However, the limited number of studies included in the analysis, and their small size, did not allow us to perform such analysis. Another limitation of meta-analyses may be publication bias, which can lead to the overestimation of the treatment effect. Specifically, negative studies (i.e. no treatment effect) are less likely to be submitted and published than positive studies, especially when studies are small, unless the study is well powered and the negative result is of exceptionally high relevance. A funnel plot analysis of our results showed moderate heterogeneity, but found no significant discrepancies suggestive of publication bias. As the number and size of the studies in this meta-analysis are small, and since other methods to detect publication bias have other limitations, we did not use any additional formal testing.
Our review of the available evidence suggests that supplemental i.v. crystalloids may reduce several PONV outcomes. However, due to the limited number of trials and the small size of the trials themselves, well-powered studies, ideally including endocrine and autonomic data, are still needed. 
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